Sodium-glucose cotransporter 2-associated perioperative ketoacidosis: a protocol for SAPKA systematic review

Hiroyuki Seki, M.D., Ph.D.1, Satoshi Ideno, M.D., Ph.D.2, Toshiya Shiga, M.D., Ph.D.3, Hidenobu Watanabe, M.D.1, Motoaki Ono, M.D.1, Akira Motoyasu, M.D.1, Hikari Noguchi, M.D.1, Kazuya Kondo, M.D.1, Takahiro Yoshikawa, M.D.1, Hiroshi Hoshijima, D.D.S., Ph.D.4, Shunsuke Hyuga, M.D., Ph.D.5, Miho Shishii, M.D.5, Ai Nagai, M.D.5, Midoriko Higashi, M.D., Ph.D.6, Takashi Ouchi, M.D., Ph.D.7, Kazuki Yasuda, M.D., Ph.D.8, Norifumi Kuratani, M.D., Ph.D., M.P.H.9

1Department of Anesthesiology, Kyorin University School of Medicine
2Department of Anesthesiology, Kawasaki Municipal Hospital
3Department of Anesthesiology, International University of Health and Welfare, School of Medicine
4Division of Dento-oral Anesthesiology, Tohoku University Graduate School of Dentistry
5Department of Anesthesiology, Kitasato University School of Medicine
6Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical Sciences, Kyushu University
7Department of Anesthesiology, Tokyo Dental College Ichikawa General Hospital
8Department of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine
9Department of Anesthesia, Saitama Children’s Medical Center

* Corresponding Author: Hiroyuki Seki
Mailing address: 6-20-2 Shinkawa Mitaka, Tokyo 181-8611, Japan
Phone number: 81-422-47-5511
E-mail address: hshiroyukiseki@gmail.com

Keywords: sodium-glucose cotransporter 2 inhibitors, ketoacidosis, diabetic ketoacidosis, systematic review, case reports
Abstract

**Background:** In recent years, reports have increased regarding patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) who develop severe ketoacidosis during the perioperative period. This systematic review aims to extrapolate precipitating factors from case reports of SGLT2i-associated perioperative ketoacidosis.

**Methods:** Two independent researchers will search PubMed, EMBASE, and Web of Science, up to June 1, 2022, with no language restrictions, to identify reports of perioperative ketoacidosis associated with SGLT2i use. We will include case reports/series describing patients taking SGLT2i who developed ketoacidosis (defined as blood pH < 7.3 and blood or urine ketone positivity) pre-, intra-, or postoperatively up to 30 days following surgery. Patients for whom SGLT2i was newly prescribed postoperatively and those for whom the diagnosis of ketoacidosis does not fulfill our criteria will be excluded.

**Competing interest statement:** Dr. Yasuda reports receiving grants from Ono Pharmaceutical and Mitsubishi Tanabe Pharma Corporation.

**Funding statement:** The Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) (Grant Number 21K06676) funded this study.
Introduction
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) comprise an anti-diabetic drug class. Aside from lowering the blood glucose levels, this type of drug also reduces the hemoglobin A1c level, promotes weight loss, lowers blood pressure, and provides cardiorenal protection1. However, these inhibitors have been associated with adverse events such as ketoacidosis, which is fatal. Despite the increasing number of reports on SGLT2i-associated ketoacidosis, specifically during the perioperative period, its etiology and risk factors have not been fully elucidated. As the prescription of SGLT2i becomes more ubiquitous, it is necessary to understand the clinical features of SGLT2i-associated ketoacidosis. This systematic review aimed to extrapolate the precipitating factors for SGLT2i-associated perioperative ketoacidosis (SAPKA) by summarizing the currently available case reports.

Methods
This study will be conducted in compliance with the preferred reporting items systematic reviews and meta-analysis 2020 statement2). The preliminary search has been completed, and the formal search will start on June 1, 2022. The anticipated date of completion is December 31, 2022.

Eligibility criteria
We will include case reports/series involving patients taking SGLT2i who developed ketoacidosis (defined as a blood pH <7.3 and blood or urine ketone positivity) preoperatively, intraoperatively, or up to 30 days postoperatively. Letters, reviews, and conference abstracts will be included. Patients newly prescribed with SGLT2i after surgery and those who do not fulfill the criteria for ketoacidosis will be excluded. Cases in which pH value is unclear, but the authors state “acidosis” will be included.

Search strategy and study selection
Studies will be obtained from electronic databases, including PubMed, EMBASE, and Web of Science, by two independent researchers (H.S. and S.I.). The search will be conducted on June 1, 2022, without language restrictions for identifying perioperative ketoacidosis associated with SGLT2i. The full search strategy is described in Table 1. The reference lists of all identified studies and those of previous meta-analyses on similar topics will be checked. The titles and abstracts of the obtained references will be independently screened by two reviewers (H.S. and S.I.), and the full-text articles of relevant abstracts will be collected. Disagreements will be resolved by discussion or consultation with a third author (K.Y.).

Data extraction
Patient data, including age, sex, body mass index, purpose of SGLT2i prescription, comorbidities, type of diabetes, type of SGLT2i, anti-diabetic and other medications, type of surgery and anesthesia, data on withholding the agents before surgery, nature of presentation as ketoacidosis, biochemical
parameters (including serum glucose, hemoglobin A1c, pH, serum bicarbonate, partial pressure of arterial carbon dioxide, anion gap, plasma and urine ketones, and glycosuria), details of management, complications, and outcome, will be independently extracted by 14 reviewers (H.S., S.I., H.W., M.O., A.M., H.N., K.K., T.Y., H.H., S.H., M.S., A.I., M.H., and T.O.) working in seven teams. In this study, ketoacidosis is defined as a blood pH <7.30, along with blood or urine ketone positivity based on several guidelines. Disagreements will be resolved by discussion or consultation with a third author (K.Y.).

**Assessment of methodological quality of the cases**
The methodological quality of the cases will be assessed using a previously published method. The quality of the report will be graded from zero (low) to five (high). Disagreements will be resolved by discussion or consultation with a third author (K.Y.).

**Strategy for data synthesis**
A narrative synthesis of the findings of the included studies will be provided. It will be structured around the type of intervention, target population characteristics, type of outcome, and intervention content.

**Dissemination plans**
The findings of this study will be submitted to peer-reviewed journals, and abstracts will be submitted to relevant national and international meetings.

**Author’s contribution**
Review design/planning: H.S., S.I., N.K., T.S., K.Y.
Writing manuscript: H.S., N.K., T.S., K.Y.
Critical review: All authors

**Acknowledgement**
None.

**Declaration of interest**
Dr. Yasuda reports grants from Ono Pharmaceutical and Mitsubishi Tanabe Pharma Corporation.

**Funding**
This work was supported by the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (C) (Grant Number 21K06676).
References


Table 1. Search strategies for each database

<table>
<thead>
<tr>
<th>Database</th>
<th>Search Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>(&quot;SGLT2 inhibitors&quot; OR &quot;sodium-glucose cotransporter 2 inhibitors&quot; OR &quot;canagliflozin&quot;[MeSH Terms] OR &quot;canagliflozin&quot;[All Fields]) OR (&quot;dapagliflozin&quot;[Supplementary Concept] OR &quot;dapagliflozin&quot;[All Fields] OR &quot;dapagliflozin s&quot;[All Fields]) OR (&quot;empagliflozin&quot;[Supplementary Concept] OR &quot;empagliflozin&quot;[All Fields]) OR (&quot;ertugliflozin&quot;[Supplementary Concept] OR &quot;ertugliflozin&quot;[All Fields]) OR (&quot;ipragliflozin&quot;[Supplementary Concept] OR &quot;ipragliflozin&quot;[All Fields]) OR (&quot;1 5 anhydro 1 5 4 ethoxybenzyl 2 methoxy 4 methylphenyl 1 thioglucitol&quot;[Supplementary Concept] OR &quot;1 5 anhydro 1 5 4 ethoxybenzyl 2 methoxy 4 methylphenyl 1 thioglucitol&quot;[All Fields] OR &quot;luseogliflozin&quot;[All Fields]) OR (&quot;2s 3r 4r 5s 6r 2 4 chloro 3 4 ethoxybenzyl phenyl 6 methylthio tetrahydro 2h pyran 3 4 5 triol&quot;[Supplementary Concept] OR &quot;2s 3r 4r 5s 6r 2 4 chloro 3 4 ethoxybenzyl phenyl 6 methylthio tetrahydro 2h pyran 3 4 5 triol&quot;[All Fields] OR &quot;sotagliflozin&quot;[All Fields]) OR (&quot;6 4 ethylphenyl methyl 3 4 5 6 tetrahydro 6 hydroxymethyl spiro isobenzofuran 1 3h 2 2h pyran 3 4 5 triol&quot;[Supplementary Concept] OR &quot;6 4 ethylphenyl methyl 3 4 5 6 tetrahydro 6 hydroxymethyl spiro isobenzofuran 1 3h 2 2h pyran 3 4 5 triol&quot;[All Fields] OR &quot;tofogliflozin&quot;[All Fields]) AND (&quot;ketosis&quot;[MeSH Terms] OR &quot;ketosis&quot;[All Fields] OR &quot;ketoacidosis&quot;[All Fields]) OR (&quot;acidosis&quot;[MeSH Terms] OR &quot;acidosis&quot;[All Fields]) AND (&quot;acidosis OR acidosis&quot;)</td>
</tr>
<tr>
<td>Web of Science</td>
<td>(“SGLT2 inhibitors” OR “sodium-glucose cotransporter 2 inhibitors” OR canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR ipragliflozin OR luseogliflozin OR sotagliflozin OR tofogliflozin) AND (ketoacidosis OR acidosis)</td>
</tr>
<tr>
<td>EMBASE</td>
<td>(“SGLT2 inhibitors” OR “sodium-glucose cotransporter 2 inhibitors” OR canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR ipragliflozin OR luseogliflozin OR sotagliflozin OR tofogliflozin) AND (ketoacidosis OR acidosis)</td>
</tr>
</tbody>
</table>